PATENT CLAIM ANALYSIS

Application Number: 15767618
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "231100"]

Abstract:
The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Claim (Index 5):
The vaccine of any one of  claims 1 - 4 , wherein the vaccine comprises at least two RNA polynucleotides, each having an open reading frame encoding at least one HSV antigenic polypeptide or an immunogenic fragment thereof selected from HSV-2 glycoprotein B or an immunogenic fragment thereof, HSV-2 glycoprotein C or an immunogenic fragment thereof, HSV-2 glycoprotein D or an immunogenic fragment thereof, HSV-2 glycoprotein E or an immunogenic fragment thereof, HSV-2 glycoprotein IS or an immunogenic fragment thereof, and HSV-2 ICP4 protein or an immunogenic fragment thereof, wherein the hMPV antigenic polypeptide encoded by one of the open reading frames differs from the hMPV antigenic polypeptide encoded by another of the open reading frames.

Metadata:
- Claim Count in Document: 70.0
- Percentile: 91.0
- Lexical Diversity: 1.24
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15674585', '15674591', '15674599', '15674569', '15091123']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7544976956619025
- 35 USC 102 Novelty (BERT): 0.560869757893048
- Combined Prediction Score: 0.7351349018850171
- Mean Citation Score: 413.72095800000005
- Max Citation Score: 439.89752
- Similarity Product: 322.86360592847353

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test